pyrroline has been researched along with Insulin Resistance in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bousquet, P; Chetrite, G; Fellmann, L; Fève, B; Gasparik, V; Gigou, L; Greney, H; Julien, C; Lacolley, P; Max, JP; Muscat, A; Niederhoffer, N; Oréa, V; Pizard, A; Regnault, V | 1 |
| Boddu, SP; Du, M; Hua, Y; Kandadi, MR; Li, J; Rajanna, PK; Ren, J; Sreejayan, N; Unnikrishnan, MK | 1 |
2 other study(ies) available for pyrroline and Insulin Resistance
| Article | Year |
|---|---|
A new pyrroline compound selective for I1-imidazoline receptors improves metabolic syndrome in rats.
Topics: 3T3-L1 Cells; Adiponectin; Aniline Compounds; Animals; Blood Pressure; Body Weight; Glucose Intolerance; Glucose Tolerance Test; Imidazoline Receptors; Insulin Resistance; Kidney; Lipids; Male; Metabolic Syndrome; Mice; Pyrroles; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Surface Plasmon Resonance; Sympathetic Nervous System | 2013 |
2-(3,4-Dihydro-2H-pyrrolium-1-yl)-3oxoindan-1-olate (DHPO), a novel, synthetic small molecule that alleviates insulin resistance and lipid abnormalities.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Drugs, Investigational; Hypoglycemic Agents; Indans; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Mice, Transgenic; Pyrroles | 2010 |